Jost Wolfgang H, Tönges Lars
Parkinson-Klinik Ortenau, Wolfach, Germany.
Klinik für Neurologie, Ruhr-Universität Bochum, St. Josef-Hospital, Bochum, Germany.
Fortschr Neurol Psychiatr. 2022 Dec;90(12):565-570. doi: 10.1055/a-1771-6225. Epub 2022 Feb 28.
In Parkinson's disease, the focus has long been on motor symptoms and therapy with dopaminergic substances. In recent years, the importance of non-motor symptoms has been increasingly recognized, as they occur early in the course of the disease and restrict considerably the quality of life. However, this also made the need for treatment of non-dopaminergic deficits obvious. Adenosine A receptor antagonists were identified as an additional therapy, since the adenosine A receptors are non-dopaminergic and selectively localized in the basal ganglia. This means that the striato-thalamo-cortical loops can be modulated. An adenosine A receptor antagonist was already approved in Japan in 2013 and in the USA in 2019 as an add-on to L-DOPA. Approval for this drug in Europe is expected in the near future. In this overview, we present the theoretical basis and current data on its efficacy and therapeutic use.
在帕金森病中，长期以来重点一直放在运动症状以及使用多巴胺能物质进行治疗上。近年来，非运动症状的重要性日益得到认可，因为它们在疾病进程中出现较早，并且极大地限制了生活质量。然而，这也使得治疗非多巴胺能缺陷的必要性变得显而易见。腺苷A受体拮抗剂被确定为一种额外的治疗方法，因为腺苷A受体是非多巴胺能的，并且选择性地定位于基底神经节。这意味着纹状体 - 丘脑 - 皮质环路可以被调节。一种腺苷A受体拮抗剂已于2013年在日本获批，并于2019年在美国获批作为左旋多巴的附加药物。预计该药物在欧洲不久后也会获批。在本综述中，我们介绍了其疗效和治疗用途的理论基础及当前数据。
